We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Different Test Systems Analytical Performance Evaluated for Serum Creatinine

By LabMedica International staff writers
Posted on 13 Jan 2022
Print article
Image: The cobas CREP2 reagent kit: an in vitro test for the quantitative determination of creatinine in serum, human plasma and urine (Photo courtesy of Roche Diagnostics)
Image: The cobas CREP2 reagent kit: an in vitro test for the quantitative determination of creatinine in serum, human plasma and urine (Photo courtesy of Roche Diagnostics)
Creatinine is a breakdown product of creatine phosphate from muscle and protein metabolism. It is produced and released by the body at a constant rate into the blood, and it is then carried to the kidneys through the blood circulation.

In clinical practice, the level of serum creatinine (SCr) is generally used as a significant indicator for renal function evaluation. SCr determination is a widely applied diagnostic test to evaluate glomerular filtration rate (GFR) that when renal function is impaired, the creatinine level rises. Clinical methods for serum creatinine determination include chemical and enzymatic methods.

Clinical Laboratorians at the University of Chinese Medicine (Guangzhou, China) obtained serum samples by collecting surplus samples from routine creatinine tests. Specimens for method comparison study were collected from left-over clinical 34 patient samples, with creatinine levels ranging from 45 to 1,610 μmol/L. Precision, accuracy, linearity, dilution, lower limit of measurement and analytical interference were studied between two test systems.

The scientists used the open test system, namely the Shino-Test creatinine reagent kit (Shino-Test Corp., Tokyo, Japan), and the Roche Cobas 8000 c702 chemistry analyzer (Roche Diagnostics, Mannheim, Germany) to determine creatinine levels. The determination results were analyzed and compared with those obtained from the matched test system, Roche creatinine reagent kit and the same analyzer. An interference study was carried out by adding different solutions of interferents to serum pools at three levels of creatinine. To study the influence of hemolysis, hemolysate was added to each serum pool aliquot. Interference studies of vitamin C or dobutamine were carried out by mixing serum pool aliquots with serial dilutions of vitamin C solution or dobutamine injection.

The investigators reported that the performance of SCr from the open test system was in compliance with the matched test system with good precision, accuracy, and linearity. In presence of most common interferents, both test systems could lead to accurate creatinine results except for the existence of specified drugs. For dobutamine, the open test system showed better anti-interference performance than the matched system. The results showed that either matched test system or open test system presented extremely low imprecision at each level evaluated.

The authors concluded that their study provided referable opinions for clinical laboratory selection on the test system and a framework for future analogous studies based on different test systems. Clinicians and laboratory professionals should be mindful of potential interference caused by specified medications such as calcium dobesilate and dobutamine because an inaccurate creatinine result may lead to serious untoward consequences. The study was published on December 26, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
University of Chinese Medicine
Shino-Test Corp
Roche Diagnostics

Gold Supplier
Real-Time PCR System
CFX Opus 384 System
Automatic Urine Sediment Analyzer
POC Clinical Chemistry Analyzer
Automatic Nucleic Acid Purification System
GenePure Pro

Print article
IIR Middle East


Molecular Diagnostics

view channel

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more


view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.